On this day in Santa Clarita history, MannKind Corporation announced the FDA approval of AFREZZA, a fast-acting diabetes medication that is taken through inhalation. The medicine was introduced as an alternative to injection; patients are given an inhaler to use before meals, with the levels peaking 12 to 15 minutes after administration and lasting up to 3 hours. “Approval of ...

Ed. Note: The following is a news release provided by MannKind Corp.  A new CEO has been announced by therapeutic company MannKind to replace interim CEO Alfred Mann, who has held the position since November. Don’t miss a thing. Get breaking Santa Clarita news alerts delivered right to your inbox. The corporation announced Duane M. DeSisto as its president and chief executive ...

A Valencia biomedical company announced the release of a first-of-its-kind insulin inhaler, Afrezza, in a statement. Don’t miss a thing. Get breaking Santa Clarita news alerts delivered right to your inbox. Sanofi and Valencia-based MannKind Corp. announced Afrezza (insulin human) Inhalation Powder, the only inhaled insulin, is now available by prescription in U.S. retail pharmacies nationwide. Afrezza is approved by the U.S. ...